National Pension Service Boosts Stake in Regeneron Pharmaceuticals, Inc. $REGN

National Pension Service increased its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 7.1% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 271,066 shares of the biopharmaceutical company’s stock after purchasing an additional 18,020 shares during the quarter. National Pension Service owned 0.25% of Regeneron Pharmaceuticals worth $142,310,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Proficio Capital Partners LLC grew its stake in Regeneron Pharmaceuticals by 6.2% in the 1st quarter. Proficio Capital Partners LLC now owns 327 shares of the biopharmaceutical company’s stock valued at $207,000 after acquiring an additional 19 shares during the period. Cove Private Wealth LLC lifted its holdings in Regeneron Pharmaceuticals by 4.5% during the first quarter. Cove Private Wealth LLC now owns 460 shares of the biopharmaceutical company’s stock valued at $292,000 after purchasing an additional 20 shares in the last quarter. Marino Stram & Associates LLC lifted its holdings in Regeneron Pharmaceuticals by 5.3% during the second quarter. Marino Stram & Associates LLC now owns 396 shares of the biopharmaceutical company’s stock valued at $208,000 after purchasing an additional 20 shares in the last quarter. Activest Wealth Management grew its position in shares of Regeneron Pharmaceuticals by 110.5% in the first quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 21 shares during the period. Finally, CX Institutional increased its stake in shares of Regeneron Pharmaceuticals by 7.9% during the second quarter. CX Institutional now owns 302 shares of the biopharmaceutical company’s stock worth $159,000 after purchasing an additional 22 shares in the last quarter. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Trading Up 1.1%

Shares of NASDAQ:REGN opened at $681.72 on Thursday. Regeneron Pharmaceuticals, Inc. has a 52 week low of $476.49 and a 52 week high of $823.56. The company’s 50 day moving average is $593.81 and its two-hundred day moving average is $569.58. The company has a market cap of $71.65 billion, a PE ratio of 16.32, a P/E/G ratio of 2.03 and a beta of 0.31. The company has a current ratio of 4.06, a quick ratio of 3.72 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 EPS for the quarter, topping analysts’ consensus estimates of $9.73 by $2.10. Regeneron Pharmaceuticals had a net margin of 32.13% and a return on equity of 13.76%. The firm had revenue of $3.75 billion during the quarter, compared to the consensus estimate of $3.57 billion. During the same quarter in the previous year, the firm posted $12.46 earnings per share. The company’s revenue was up .9% compared to the same quarter last year. Equities analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 5th. Shareholders of record on Thursday, November 20th will be paid a $0.88 dividend. This represents a $3.52 annualized dividend and a yield of 0.5%. The ex-dividend date is Thursday, November 20th. Regeneron Pharmaceuticals’s dividend payout ratio is currently 8.43%.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the stock. Jefferies Financial Group raised their price target on shares of Regeneron Pharmaceuticals from $813.00 to $831.00 and gave the company a “buy” rating in a research note on Wednesday, August 27th. Wells Fargo & Company upped their price objective on shares of Regeneron Pharmaceuticals from $580.00 to $615.00 and gave the company an “equal weight” rating in a research note on Wednesday, October 29th. Guggenheim increased their price objective on shares of Regeneron Pharmaceuticals from $815.00 to $865.00 and gave the company a “buy” rating in a report on Wednesday, October 29th. Royal Bank Of Canada upped their price target on Regeneron Pharmaceuticals from $704.00 to $708.00 and gave the company a “sector perform” rating in a research report on Wednesday, October 29th. Finally, Bank of America boosted their price target on shares of Regeneron Pharmaceuticals from $543.00 to $627.00 and gave the company an “underperform” rating in a research report on Wednesday, October 29th. Three research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $796.57.

Insider Activity

In other news, VP Jason Pitofsky sold 431 shares of the stock in a transaction dated Friday, November 7th. The shares were sold at an average price of $651.43, for a total transaction of $280,766.33. Following the completion of the sale, the vice president owned 4,233 shares in the company, valued at approximately $2,757,503.19. This represents a 9.24% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Christine A. Poon sold 6,500 shares of the firm’s stock in a transaction dated Wednesday, October 29th. The stock was sold at an average price of $654.27, for a total value of $4,252,755.00. Following the transaction, the director directly owned 2,352 shares in the company, valued at approximately $1,538,843.04. This represents a 73.43% decrease in their position. The SEC filing for this sale provides additional information. Company insiders own 7.02% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.